Disturbed homocysteine metabolism is associated with cancer

Abstract

Hyperhomocysteinemia/Homocysteinuria is characterized by an increased level of toxic homocysteine in the plasma. The plasma concentration of homocysteine is 5–15 μmol/L in healthy individuals, while in hyperhomocysteinemic patients, it can be as high as 500 μmol/L. While increased homocysteine levels can cause symptoms such as osteoporosis and eye lens dislocation, high homocysteine levels are most closely associated with cardiovascular complications. Recent advances have shown that increased plasma Hcy is also a fundamental cause of neurodegenerative diseases (including Alzheimer’s disease, Parkinson’s disease, and dementia), diabetes, Down syndrome, and megaloblastic anemia, among others. In recent years, increased plasma homocysteine has also been shown to be closely related to cancer. In this review, we discuss the relation between elevated plasma Hcy levels and cancer, and we conclude that disturbed homocysteine metabolism is associated with cancer. Future clinical perspectives are also discussed.

Cancer: Links with homocysteine

Cancer can be added to the wide range of diseases known to be associated with elevated blood levels of the small amino acid homocysteine. Abnormally high levels of this compound are already known to contribute to conditions including cardiovascular problems, neurodegenerative diseases, neural tube defects, Down’s syndrome, diabetes and megaloblastic anemia. This review, by Laishram R. Singh and colleagues at the University of Delhi, India, concludes that disturbed homocysteine metabolism is associated with many forms of human cancer. The authors discuss a range of genetic, epigenetic and environmental factors that may be involved in the cause and effect relationships between homocysteine metabolism and cancer. It is particularly interesting that low folate (vitamin B9) levels result in high homocysteine levels, and vice versa. Further research may yield insights leading to new forms of cancer treatment and diagnosis.

Introduction

Homocystinuria is an inborn error in the metabolic pathways of sulfur-containing amino acids and is characterized by an increase in the level of toxic homocysteine (Hcy) in the serum¹. Mutations in cystathionine beta synthase (CBS), an enzyme present at the branch point between the trans-sulfuration and remethylation pathways, are the basic cause of homocysteinemia. The term “hyperhomocysteinemia” is also used to describe the elevated Hcy serum level due to other genetic (CBS-independent) and environmental factors². In a normal, healthy individual, the serum Hcy level is between 5–15 μM, but it can increase to 50 μM in mild cases and to 500 μM in severe cases of homocysteinemia (de Koning, Werstuck et al. 2003). This hyperhomocysteinemic condition is closely related to many disease conditions (Table 1). It is believed that increased homocysteine levels lead to various cardiovascular complications (Table 1)^3,4 If the Hcy level is left uncontrolled, patients ultimately die of stroke⁵. Further studies have also revealed that elevated plasma Hcy level is one of the key factors associated with neurodegeneration, diabetes, Down syndrome, neural tube defects, and megaloblastic anemia (see Table 1)^2,4,6–9. Hyperhomocysteinemia has also been connected to various other clinical complications, including ectopic lentis, scoliosis, megaloblastic anemia, knocked knees, long limbs, and arachnodactyly, among others (Table 1)^4,10–12. Recent advances have proven that there is a close link between hyperhomocystinuria and cancer (see Fig. 1). First, higher levels of plasma homocysteine have been observed cancer patients, and venous thromboembolism (VTE) is the second most common cause of death in cancer patients. Second, several polymorphisms in the enzymes involved in the Hcy detoxification pathways (the trans-sulfuration and remethylation) have close clinical ties to several cancer types^13–23. Third, folate, which is pivotal for cell proliferation, has an inverse relation with Hcy. Fourth, Hcy has also been proposed as a potential tumor biomarker for a variety of cancers²⁴. In this review, we have systematically discussed these important key events in detail and revealed that defects in Hcy metabolism may lead to cancer. Future clinical perspectives have also been described.

Table 1.

Homocysteinemia and its associated disorders

Complication	Associated diseases	References
Cardiovascular diseases	Thromboembolism	130, 131
	Coronary artery	132
	Atherosclerosis	133, 134
	Vascular dementia	135, 136
	Congenital heart defects	137, 138
	Stroke	139, 140
Neurodegeneration	Alzheimer’s	6
	Parkinson	141, 142
	Schizophrenia	143, 144
	Dementia	145, 146
	Depression	147, 148
Diabetes	—	149, 150
Down’s syndrome	—	151
Megaloblastic anemia	—	152
Other diseases	Neural tube defects	55
	Nonsyndromic oral cleft	153
	Ectopic lentis	6, 139, 140
	Scoliosis	154
	Knocked knees	154
	Long limbs	154
	Arachnodactyly	154
Cancer	Refer to Fig. 3

Fig. 1.

Association between hyperhomocysteinemia and various cancer types

I (a) Low folate levels help build plasma Hcy

Homocysteine is a sulfur-containing, nonprotein, toxic amino acid found in the pathway for the interconversion of two amino acids: methionine and cysteine. Homocysteine is metabolized via two different pathways: remethylation and trans-sulfuration^25,26. When there is an excess of cellular methionine, the trans-sulfuration pathway plays a crucial role in Hcy metabolism, converting Hcy to cystathionine via CBS, which requires pyridoxal 5′-phosphate as a co-factor^25,27. When the cellular methionine level is low, Hcy is remethylated back to methionine in a betaine- or folate-dependent reaction. In the betaine-dependent pathway, the enzyme betaine-homocysteine S-methyltransferase (BHMT)^28,29 catalyzes the incorporation of a methyl group from betaine into homocysteine to form methionine. In the folate-dependent pathway, Hcy acquires a methyl group from N-5-methyltetrahydrofolate with the help of 5-methyltetrahydrofolate-homocysteine methyltransferase (MTR) (also known as methionine synthase). Methionine synthase requires vitamin B12 for its functionality, and the reaction also involves recycling of tetrahydrofolate (from N-5-methyltetrahydrofolate), which may eventually be used for nucleotide biosynthesis³⁰. Methionine synthase, therefore, couples the folate and Hcy metabolism pathways (Fig. 2). Since the generation of tetrahydrofolate depends on the input of exogenous folate for folate metabolism (as outlined in Fig. 2), low folate levels ultimately result in substrate limitation for methionine synthase, thereby affecting the remethylation pathway. Thus, low folate levels result in a high plasma Hcy concentration and vice versa.

Fig. 2.

Folate metabolism is linked to the homocysteine metabolic pathway

Many factors that affect the folate level have also been found to disturb the Hcy level. For instance, diets deficient in folate, cobalamin, and vitamin B6³¹ and use of anti-folate drugs (including anticonvulsants and other neurological drugs³²) directly increase the plasma Hcy level. Drugs that elevate the Hcy level (e.g., laxatives, diuretics, birth control pills, anti-inflammatory drugs, immune suppressants) also reduce the folic acid levels^33–36. Other conditions, including alcohol consumption^13,18, smoking, diabetes, and psoriasis³⁷, among others, are responsible for reducing the plasma folate level by affecting the folate level. Therefore, it is important to take folate supplements to restore the depleted Hcy pool.

I (b) Low plasma folate levels lead to cancer predisposition

Folate is not only involved in nucleotide biosynthesis but also required for the conversion of deoxyuridine monophosphate (dUMP) into thymidine monophosphate³⁸. Under normal conditions, thymidylate synthetase (TYMS) converts dUMP into thymidine monophosphate using 5,10-methylenetetrahydrofolate (derived from folate) as a methyl group donor. If folate is limiting, dUMP accumulates because its key methyl donor, 5,10-methylenetetrahydrofolate, is absent. These conditions lead to an imbalance in the deoxyribonucleotide pool, and, consequently, there is excessive incorporation of uracil into DNA instead of thymine; this defect is normally repaired by the enzyme uracil DNA glycosylase, which removes the misincorporated uracil from the DNA strand³⁹. When the folate concentration is disturbed (due to increased Hcy levels) the DNA glycosylase fails to cope with the DNA repair burden. This situation leads to chromosomal damage, which may then lead malignant transformation in cells. Furthermore, excision repair of uracil residues 12 base pairs apart can lead to double strand breaks, which may increase DNA instability due to relaxed DNA supercoiling and chromosomal remodeling, both of which can cause an increase in malignant transformation. Chromosomal aberrations are also associated with inappropriate differentiation and morphology of lineage-specific cells, features often associated with tumors⁴⁰.

Low plasma folate levels are also linked to cancer is via DNA methylation. DNA methylation is an epigenetic modification that is critical for normal genome regulation and development. Indeed, it is Hcy that is recycled to methionine with the help of methionine synthase. DNA methylation is carried out with the help of a methyl donor, S-adenosyl-l-methionine (SAM), which is obtained from methionine via an ATP-dependent reaction catalyzed by S-adenomethyl synthetase⁴¹. DNA methylation is jointly carried out by three types of DNA methyltransferases (DNMTs)—DNMT1, DNMT3a, and DNMT3b on SAM (Fig. 3). Since SAM is generated from 5-methyltetrahydrofolate (5′-MTHF) as shown in Fig. 3, low folate levels limit the substrate availability for methionine synthase, thereby resulting in DNA hypomethylation. DNA hypomethylation leads to decondensation of pericentromeric heterochromatin and the activation of retrotransposon elements⁴². Global genomic hypomethylation has been found in many types of cancer, including prostate metastatic tumors, chronic lymphocytic tumors, and hepatocellular carcinoma. Regional hypomethylation of DNA sequences is also often observed during the early stages of tumorigenesis and in abnormal nonneoplastic tissue, such as hyperplasia⁴³.

Fig. 3.

Low folate levels result in Hypomethylation

I (c) Cancer patients have high plasma Hcy levels

As mentioned in the earlier sections, there is an inverse relation between plasma Hcy and folate. In cancer patients, the plasma folate level is expected to be low because tumor cells must draw folate from the blood for de novo purine synthesis^44,45. Interestingly, as shown in Fig. 1, hyperhomocystinuria is associated with several types of cancer. It is also clear from the information in this figure that the causative relationship between homocysteine toxicity and cancer is independent of the organ/tissue and the type of cancer. Table 2 shows that all cancer types in the advanced stage exhibit high plasma Hcy levels, while there was no significant change in plasma Hcy levels in early stage cancer. Furthermore, once patients are subjected to surgery or chemotherapy, there is also a sharp increase in the plasma Hcy level, leading to a higher frequency of thromboembolic events. Because most commonly used clinical chemotherapeutic agents (such as alkylating agents, antimetabolites, methotrexate, hormones, and antagonists) are anti-folate drugs⁴⁶, their use causes a decrease in the plasma folic acid concentration. In another development, it has also been shown that older cancer patients are at a higher risk of developing hyperhomocysteinemia than are younger patients⁴⁷.

Table 2.

Polymorphisms detected in genes involved in homocysteine metabolism

Gene	Polymorphisms	Amino acid change	Cancer type	OR values	References
Methylene-tetrahydrofolate reductase (MTHFR)	677C- > T	A226V	Endometrial carcinoma	1.10	155
			Esophageal squamous cell carcinoma (SCC)	1.47	156
			Breast cancer	1.00a/1.12/1.00a	15, 99, 157
			Acute lymphocytic leukemia (ALL)	0.99/0.23	87
			Prostate cancer	0.78	158
			Colorectal cancer	1.78/1.00a/0.76	85, 159– 161
	1298A- > C	E443A	Prostate cancer	0.58	79
			Acute myeloid leukemia	0.33/1.00	87, 162
			Endometrial cancer	0.88	155
	1793G- > A	R1793E	Colorectal cancer	0.17	163
			Acute myeloid leukemia	1.00	162
Methionine synthase reductase (MTRR)	66A- > G	I22M	Leukemia	1.00a	164, 165
			Colorectal cancer	2.77/1.07	18, 165, 166
			Gastric cancer	0.74/1.39	167, 168
			Breast cancer	4.45	169
Methionine synthase (MTR)	2756A- > G	D919G	Head and neck carcinoma	1.10	170
			Colorectal cancer	1.03/0.65/2.04	161, 170, 171
			Lung cancer	1.34	172
			Hepatocellular carcinoma	1.01	170, 173
			Cervical cancer	0.27	14
			Glioblastoma multiforme	1.00a	174
			Breast cancer	1.00a	99
			Squamous cell carcinoma	1.00a	98
			Gastric cancer	1.06/1.35	168, 170, 175
			Pancreatic cancer	1.08/3.35	170, 176
Methylene-tetrahydrofolate dehydrogenase (MTHFD1)	1958G- > A	A653G	Gastric cancer	2.05	102
			Leukemia	0.80	177
	401G- > A	R134K	Gastric cancer	1.43	102
			Leukemia	0.89	177
			Ovarian cancer	0.97	178
Betaine-homocysteine methyltransferase (BHMT)	742G- > A	R239Q	Squamous cell carcinoma	1.07	179
			Breast cancer	0.98/0.12	111, 180
			Uterine carcinoma	0.64	181
			Ovarian cancer	1.01	182
			Colorectal adenoma	1.09	183
			Liver cancer	0.98	184
	595G- > A	G199S	—
	716G- > A	Q239R	—
	1218G- > T	Q406H	—
Cystathionine β-synthase (CBS)	833T- > C	I278T	—
	699C- > T	Y233Y	—
	1080C- > T	A360A	—
	572C- > T	T191M	—
	139C- > T	S466L	—
	502G- > A	V168M	—
	797G- > A	R266K	—
	1150A- > G	K384E	—
	341C- > T	A114V	—
	919G- > A	G307S	—
TCN 2	776 G > C	R259P	Colorectal adenoma	0.753	183
			Colorectal cancer	1.137	185
			Glioblastoma	1.028	174
			Primary central nervous system lymphoma	1.338	186
			Ovarian cancer	1.389	182
TYMS	TS 3́-UTR	—	Esophageal cancer	0.73	187
		—	Stomach cancer	1.12	187
	TSER	—	Breast cancer	1.09	187

^aPapers that reported no association have been given the value of 1.00

There is no clear explanation for why the Hcy levels vary between early and late stage cancer. However, we speculate that cells in the early stage might not secrete Hcy, as it facilitates the proliferation process of cancer cells⁴⁸. Studies have shown that increased homocysteine levels lead to increased cellular proliferation in Caco-2 cell lines. This enhanced proliferation can be reversed by folate supplementation in the culture medium or by supplementation with its downstream metabolites, such as 5-MTHF⁴⁹. However, advanced-stage cancer cells might secrete Hcy because a very high Hcy concentration might also be cytotoxic to the cancer cells. Therefore, it may be important for proliferating cells to maintain an optimum Hcy concentration. This speculation, however, requires further experimental validation.

I (d) Cancer patients develop thromboembolisms due to Hcy toxicity

One major symptom of hyperhomocysteinemia is the formation of venous thromboembolism (VTE). VTE is the most frequent complication and second most common cause of death among cancer patients⁵⁰. Advanced-stage cancer patients develop both hyperhomocysteinemia and VTE. Alternatively, in early cancer patients (without homocysteinuria), VTE is absent⁵¹. Indeed, the advanced-stage cancer patients have a greater risk for developing VTE, with a frequency of 5–15%^51,52 (in comparison, the risk for the normal population is 0.1%). Postchemotherapy cancer patients (who are known to be at risk for homocystinuria) account for 13% of the total pool of VTE patients⁵³. In postsurgery patients, their susceptibilities to embolism and thrombosis are increased three-fold and two-fold, respectively⁵⁴. Use of central venous catheters and hormonal adjuvant therapy (e.g., Tamoxifen) also predisposes patients to VTE⁵¹ due to increased plasma Hcy levels. Thus, there is a close link between cancer and Hcy-induced development of VTE.

The mechanism underlying the cancer-related thrombosis induced by elevated Hcy⁵⁵ is complex and not well understood. However, it has been thought to result from endothelial disturbances caused by the formation of Hcy-mediated free-radicals⁵⁶. Hcy is a pro-oxidant, and the formation of Hcy-Hcy dimers and Hcy-protein adducts that help to generate free radicals are well established. Hcy can also form a more highly reactive compound called homocysteine thiolactone. Homocysteine thiolactone has been known to form covalent adducts with lysine or arginine residues in proteins, resulting in the formation of insoluble toxic protein aggregates or amyloids^2,57,58. The deposition of such aggregates in the blood or heart may, therefore, impede normal heart function and physiology. Furthermore, modification of hemostatic proteins (via N-homocysteinylation or S-homocysteinylation) has also been reported to impede NO metabolism, which may cause biotoxicity in endothelial cells⁵⁹. Hcy also inhibits thrombomodulin and Protein C-dependent inactivation of Factor V_a;⁶⁰ therefore, blood coagulation is enhanced in the presence of Hcy. Furthermore, Hcy limits the secretion of nitric oxide (NO), leading to increased platelet aggregation and decreased antithrombic activities in the endothelial cells^61,62.

I (e) Allelic polymorphisms in sulfur metabolism genes and associated risk of cancer

Various case control and cohort studies^63–70 have shown that mutations and polymorphisms exist in genes involved in homocysteine metabolism (MTHFR, CBS, MTRR, MTR, MTHFD, BHMT, TYMS, TCN 2). Polymorphic alleles of these genes were found to be linked with neural tube defects⁷¹ and/or vascular thromboembolism^72,73, which are symptoms of hyperhomocysteinemia. Recent studies have shown that these polymorphisms are also closely associated with different cancer types (Table 2). For instance, MTHFR has ~6375 polymorphisms, consisting of 650 deletions, 05 multiple base substitutions, 140 repeat variations, and 5580 SNPs⁷⁴. Two common polymorphisms, a 677C- > T transition at codon 222 (Ala222Val)^{19,27,63,73,75} and a 1298A- > C transversion at codon 429 (Glu429Ala)^75,76, have been reported to be associated with various cancer types, including endometrial carcinoma, esophageal squamous cell carcinoma (SCC), colon cancer, acute lymphocytic leukemia (ALL), and prostate cancer. In addition to 677C- > T and 1298A- > C, there is a third polymorphism, 1793G- > A, whose frequency is very low (~ 4.6% or less) and which is confined to colorectal cancer⁷⁷. The 677C- > T polymorphism affects the protein’s catalytic activity and the 1298A- > C polymorphism affects its regulatory function^20,78. Homozygotes (677 CC, ~ 60%) are more frequent than heterozygotes (677 CT, ~ 31%), but this pattern is reversed in the case of 1298 (1298AC, ~ 53% and 1298AA, ~ 31%). The 677TT and 1298CC homozygotes were found to have reduced prostate cancer risk, as the frequencies are very low (9 and 11%, respectively)^21,79. The risk factor associated with the 677C- > T polymorphism has been found to depend on the type of cancer, as it confers a higher risk for endometrial carcinoma⁸⁰(7), esophageal SCC⁸¹, and prostate cancer^82–84, while it has little or no effect on the risk for colon cancer^14,85,86 and acute lymphoid leukemia⁸⁷. The variable behavior of 677C- > T in different cancer types indicates that the environment or genetic background might help to dictate the activity of the polymorphism. In this context⁸⁸, a number of factors have been proposed, including folate status, methionine, and the effects of alcohol consumption, to be the risk factor connecting the 677C- > T polymorphism to colorectal cancer. Another possibility is that the 677C- > T polymorphism is dominant negative in some cancer types but not in others based on the functional effect of the polymorphism.

MTRR has ~9461 polymorphisms, out of which 1051 are deletions, 01 are multiple base substitutions, 315 are repeat variations, and 8094 are SNPs⁸⁹. Out of this pool, only one polymorphism (MTRR A66G, Ile22Met)^14,18,90,91 has been studied and found to be associated with leukemia and colorectal cancer. This leukemic polymorphism has an allelic frequency of 51% in white populations^87,90 Comparison of the relationships between homozygosity and heterozygosity and colorectal cancer revealed that homozygotes (GG) have a three-fold higher risk compared with that of heterozygotes (AG)^14,92. Since the leukemic allelic frequency is very high in the white population, it is important to investigate other populations to determine if genetic background affects the frequencies or functions of polymorphic MTRR.

Similarly, MTR has ~26150 polymorphisms, out of which 2643 are deletions, 06 are multiple base substitutions, 221 are repeat variations, and 23245 are SNPs¹⁰⁵. One significant polymorphism (MTR A2756G; Asp919Gly) has been documented in MTR. This 2756A- > G variant is associated with head, esophageal and neck squamous cell carcinoma, colorectal adenoma, colorectal carcinoma, lung cancer, multiple myeloma, cervical cancer, uterine cancer, and glioblastoma multiforme^{18,24,37,93–97}. This polymorphism is associated with a decreased risk for colorectal cancer^14,90, and no correlation could be established between this MTR variant and the incidence of breast and upper gastrointestinal tract carcinomas^98,99, suggesting that the severity of the effect of the polymorphism might depend on the type of cancer.

MTHFD-1 has ~16991 polymorphisms, out of which 1913 are deletions, 07 are multiple base substitutions, 215 are repeat variations, and 14856 are SNPs¹⁰⁰. One polymorphism (1958G- > A; Ala653Gly)^97,101,102 associated with acute lymphoid leukemia, which is located within the 10-formyl THF synthetase domain, has been reported¹⁰³. No links between MTHFD variants and lung cancer risk could be established (Liu, Jin et al. 2008). Another polymorphism, (401G- > A; Arg134Lys), which is in the cyclohydrolase/dehydrogenase domain, was also reported by¹⁰², but it is associated with a low colon cancer risk.

TYMS expression is a highly regulated process that is modulated by unique tandem repeat sequences and significant polymorphisms in the 5́-UTR of the thymidylate synthase enhancer region (TSER) and in the 3́-UTR (TS1494del6b) of the gene¹⁰⁴. TYMS has ~5892 polymorphisms, out of which 1078 are deletions, 05 are multiple base substitutions, 398 are repeat variations, and 4411 are SNPs¹⁰⁵. The TSER variant is most commonly present as double- (2R) and triple- (3R) repeat sequences, although 4R, 5R, and 9R repeats also exist. 3R sequences show higher translational efficiency than 2R sequences. Homozygous 3R/3R subjects show higher TYMS protein expression and higher enzyme activity¹⁰⁶. The second TYMS polymorphism identified is a 6 bp deletion/insertion at bp 1494 in the 3́-UTR of the TYMS gene. Several lines of evidence suggest that variation in the TYMS gene is associated with cancer risk. However, the risk factor associated with these polymorphisms depends on the type of cancer. In the cases of stomach, colorectal, and lung cancer, the TYMS enzyme activity and mRNA expression were found to be increased.

Transcobalamin II (TCN II) is a serum protein that transports vitamin B12 (cobalamin) from the ileum to other tissues. Vitamin B12 serves as an important molecule in the remethylation of methionine from Hcy and is important for the transformation of MTHF to THF. TCN-2 has ~8291 polymorphisms, out of which 1183 are deletions, 02 are multiple base substitutions, 146 are repeat variations, and 6960 are SNPs¹⁰⁷. One common polymorphism in the TCN 2 gene is a G to C substitution (776 G > C, rs1801198) that results in replacement of a proline with an arginine¹⁰⁸ In a recent meta-analysis, it was shown that subjects with the rs1801198 GG genotype had significantly lower concentrations of holotranscobalamin and higher Hcy levels compared to subjects with the rs1801198 CC genotype. This polymorphism has also been shown to be associated with different cancers, including colorectal cancer, ovarian cancer, glioblastoma, among others. However, most of the cancer types did not have close association, as indicated by OR values near or equal to 1. Colorectal cancer, ovarian cancer, and central nervous system lymphoma, on the other hand, have higher OR values and, therefore, exhibit significant association (Table 2). Therefore, it is thought that the TCN 2 polymorphism rs1801198 significantly alters the circulating holotranscobalamin levels. Since TCN 2 plays a vital role in vitamin B12 metabolism, it is reasonable to suspect that the rs1801198 polymorphism may affect pathological conditions related to vitamin B12 deficiency.

BHMT has ~5271 polymorphisms, out of which 484 are deletions, 01 multiple base substitution, 140 are repeat variations, and 4648 are SNPs¹⁰⁹. Out of these variations, three significant mutations (Gly199Ser, Glu239Arg, and Glu406His) and one polymorphism have been examined. The polymorphism is the G to A substitution (742 G > A, rs3733890), which replaces arginine by glutamine at codon 239. A study incorporating meta-analysis was performed to investigate the rs3733890 polymorphism and cancer susceptibility. It was shown that this polymorphism showed no statistically significant association with increased risk of various cancers, including head and squamous cell carcinoma, breast cancer, ovarian cancer, colorectal adenoma, and liver cancer. However, a negative association was observed in uterine cervical cancer (Table 2).

CBS has ~6617 polymorphisms, out of which 573 are deletions, 04 are multiple base substitutions, 1059 are repeat variations, and 4981 are SNPs¹¹⁰. Interestingly, none of these mutations have been shown to cause any significant predisposition towards any type of cancer¹¹¹. This observation opens an avenue for future research studies focusing on understanding and identifying the frequencies of BHMT and CBS genotypes and their associations with and prevalence in different cancer types.

I (f) CBS is associated with cancer via H₂S production

H₂S, which is a signaling molecule, is substantially involved in vasorelaxation, acting as a neuromodulator^112,113. Recently, H₂S has gained attention in cancer due to its cytotoxic and cytoprotective effects. It plays a key role in the bioenergetics of tumor cells and stimulates their proliferation, migration, and invasion^114–116. In humans, CBS normally catalyzes the condensation of serine with homocysteine to produce cystathionine and water, a pivotal reaction in the trans-sulfuration pathway. In an alternative reaction, CBS can produce H₂S via β-elimination and β-replacement¹¹⁷ reactions. The β-elimination reaction involves catalysis of cysteine by CBS with corresponding H₂S production, whereas in the β-replacement mechanism, the reaction between L-cysteine and 2-mercaptoethanol enables CBS to produce H₂S. Various clinical studies have shown that there is CBS overexpression and, hence, increased H₂S production, in many cancer types, including colon, ovarian, gastric, colorectal, prostate, gastroesophageal cancer, and endometrial cell angiogenesis^118–121 (Fiorucci, Antonelli et al.;¹¹⁸ Guo, Gai et al.;¹¹⁹ Bhattacharyya, Saha et al.;¹²⁰ Szabo, Coletta et al. 2013; Modis, Coletta et al. 2014; Hellmich, Coletta et al.;¹²² Katsouda, Bibli et al¹²¹.). The role of H₂S in cancer has been elucidated. It is known to enhance tumor growth and increase cellular proliferation by (i) stimulating cellular bioenergetics, (ii) activating proliferative, migratory, and invasive signaling pathways, and (iii) enhancing angiogenesis in tumors¹²². Other studies have demonstrated that HCT116 cells (a transformed cell line) have CBS upregulation and enhanced H₂S production compared to nontransformed cells¹²³.

ShRNA-mediated silencing of CBS or suppression of its activity by pharmacological means (using aminooxyacetic acid)¹²⁴ results in reduced mitochondrial function (ATP turnover, respiratory reserve capacity, and oxygen consumption) and impaired glycolysis¹¹². A clinical study of colon cancer showed reduced angiogenesis and increased growth in xenografts derived from colon cancer patients incubated in mice treated with aminooxyacetic acid¹²⁵. Alternatively, H₂S production induces angiogenesis in various experimental models¹¹⁴. In another development¹²⁶, investigated the effects of S-adenosyl-L-methionine (SAM) on tumor bioenergetics^127,128. SAM is an allosteric activator of CBS that binds to the regulatory domain of CBS. The study revealed that SAM enhances H₂S production of in the HCT116 cancer cell line. Mechanistically, it is not completely known how H₂S helps to stimulate tumor growth¹²⁹. However, it has been argued that H₂S serves as an autocrine stimulator during tumor proliferation. Therefore, modulation of the CBS and H₂S levels could help limit cancer proliferation and promote its reversal.

Conclusion

It is clear from this review that there are compelling genetic, epigenetic and environmental factors that establish a close association between disturbed Hcy metabolism and cancer. Therefore, Hcy-elevating drugs should be restrictively prescribed to cancer patients, and clinicians should closely monitor Hcy levels after chemotherapy or surgery. To date, the effects of Hcy on the growth and proliferation of tumor cells remain poorly understood. Insight into the effects of Hcy on the growth and proliferation of cancer cells would yield novel, promising strategies to curb cancer. Nevertheless, Hcy can be used as a potential tumor biomarker for a variety of cancers.

Conflict of interest

The authors declare that they have no conflict.